Celldex Q1 net loss $0.49/share; cash $380.5M; barzolvolimab Ph2 starts Q2 2022

Celldex Therapeutics, Inc.

2022-Q1 EPS reported -$0.49 revenue$174,000

Net loss of $23.1M ($0.49 per share) vs $16.5M ($0.42) a year ago; revenue fell to $0.2M from $0.7M.
Cash, cash equivalents and marketable securities $380.5M at March 31, 2022; sufficient to fund operations through 2025.
R&D expenses increased to $17.1M from $12.7M; G&A expenses $6.9M vs $4.1M, driven by clinical and commercial planning.
Phase 2 studies of barzolvolimab in chronic spontaneous and inducible urticaria to initiate Q2 2022; Phase 1b CSU data submitted to EAACI.
Barzolvolimab expansion into eosinophilic esophagitis with Phase 2 planned Q4 2022; enrollment continues in prurigo nodularis and inducible urticaria.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.